Welcome to our dedicated page for Creative Med Technology Hldgs news (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Med Technology Hldgs stock.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) generates frequent news as a clinical-stage biotechnology company advancing regenerative medicine, regenerative immunotherapy, and AI-enabled biodefense programs. News coverage on this page centers on the company’s clinical data, regulatory designations, intellectual property developments, and strategic initiatives built around its AlloStem, ImmCelz, and iPScelz platforms.
Readers can follow detailed updates on CELZ-201 (olastrocel), the company’s lead allogeneic perinatal tissue–derived cell therapy. Recent announcements include interim 180-day results from the FDA-cleared ADAPT trial in chronic lower back pain associated with degenerative disc disease, showing statistically significant and clinically meaningful improvements in functional disability and pain with a favorable safety profile. Additional news highlights FDA Fast Track designation for CELZ-201-DDT and progress in the CREATE-1 trial for new-onset Type 1 diabetes.
CELZ news also covers the company’s BioDefense Inc. subsidiary and its Burn Pit Initiative, which has received regulatory approval to proceed. Articles describe plans to build a large molecular and cellular database for veterans exposed to toxic burn pits, supported by AI-driven molecular modeling and regenerative countermeasure development using the iPScelz platform and collaborations with partners such as Greenstone Biosciences.
Investors can review press releases on patent allowances and issued patents for ImmCelz-based regenerative immunotherapy in Type 1 diabetes and heart failure, as well as corporate communications such as shareholder letters outlining platform strategy, AI integration, and clinical milestones. Capital markets updates, including warrant exercise agreements and related proxy materials, are also reflected in the news flow.
For anyone tracking CELZ, this news feed provides a centralized view of clinical trial milestones, regulatory events, biodefense initiatives, and financing disclosures that shape the company’s development as a clinical-stage biotechnology issuer.
Creative Medical Technology Holdings (NASDAQ: CELZ) has announced a $1.85 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 418,552 shares at $4.42 per share. Additionally, in a concurrent private placement, the company will issue warrants to purchase up to 837,104 shares with an exercise price of $4.42 per share, exercisable upon stockholder approval and valid for five years. Roth Capital Partners is the exclusive placement agent. The proceeds will be used for working capital and general corporate purposes. The closing is expected around October 23, 2024.
Creative Medical Technology Holdings (NASDAQ: CELZ) has initiated a program to diagnose and treat patients exposed to biological and chemical weapons. The program combines Artificial Intelligence (AI) with the company's proprietary human induced pluripotent stem cells (iPSC) from its iPSCelz® program. AI will be used to identify damage in exposed patients, and based on the clinical diagnosis, the company's validated iPSC Inducible Pluripotent Mesenchymal Cells will be used for personalized treatment. This initiative aligns with Creative Medical Technology's focus on regenerative approaches to immunotherapy, urology, neurology, and orthopedics.
Creative Medical Technology Holdings (NASDAQ: CELZ) has provided a corporate update, highlighting significant developments in 2024. The company has produced over six billion clinical-grade AlloStem™ cells, filed a Drug Master File with the FDA, and received multiple IND clearances and Orphan Drug Designation for CELZ-101. Key clinical trials for Type 1 Diabetes and Chronic Lower Back Pain are actively recruiting. Additionally, the company announced the successful generation of human insulin-producing cells via its iPSCelz™ program and expects to report $7.5 million in cash with no long-term debt as of June 30, 2024. An annual stockholders meeting is scheduled for July 19, 2024, with a significant proposal to increase the number of authorized shares from 5 million to 25 million.
Creative Medical Technology Holdings (NASDAQ: CELZ) has successfully generated human insulin-producing Islet Cells derived from induced pluripotent stem cells (iPSC) under its iPSCelz® program. This development is validated by Greenstone Biosciences and utilized in several FDA-cleared clinical programs in the U.S. The creation of these cells marks a significant milestone for the company, potentially accelerating clinical applications and saving years of research and development. CEO Timothy Warbington highlighted the cost-efficiency and regulatory adherence of the company's multiple programs while maintaining a lower burn rate compared to peers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.